GSK GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About GSK (LON: GSK)
›
GSK (LON: GSK) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 66,841 employees.
The shares were at 1827.00 GBp on 19 November 2026, roughly unchanged over 52 weeks. Its 52-week range is 1735.50 GBp to 2282.00 GBp: the price is 19.9% below the high and 5.3% above the low.
At a market capitalisation of 73.24B GBP, it trades at 17.1 times trailing earnings and 9.8 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, a discount of 34% for GSK. It pays a dividend yielding 3.66% (it pays out 64% of its earnings), against a median of 2.43% among the dividend payers in that peer group.
GSK reports return on equity of 34.9%, an operating margin of 30.5% and revenue up 4.0% year over year.
Its debt exceeds its cash by 20.84B GBP, a debt-to-equity ratio of 1.08. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 21 analysts cover the stock, with an average rating of Hold; their mean price target of 2147.38 GBp is 17.5% above the current price. The next earnings report is expected on 3 February 2027.